TWO · 6847.TWO
Puriblood Medical Co., Ltd.
NT$71.70+NT$0.20 (+0.28%)
Puriblood Medical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 23.48% below the high.
Loading market information…
TWO · 4139.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Ma Kuang Healthcare Holding Limited’s quoted price sits in the upper half of its reported 52-week range, 7.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ma Kuang Healthcare Holding Limited’s forward annual dividend is NT$1.60 per share, paid annual. The forward yield is 3.81% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ma Kuang Healthcare Holding Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ma Kuang Healthcare Holding Limited, established in 2009 and headquartered in Kaohsiung, Taiwan, functions as an investment holding firm with a broad international and domestic presence in the healthcare sector. The company's core business involves a comprehensive range of medical services, including general community healthcare and specialized traditional Chinese medicine. Beyond direct patient care, Ma Kuang provides Chinese medicinal products, medical management training, and educational support. Its diverse offerings extend to homestay and guardianship services for overseas students, as well as a variety of consulting services encompassing corporate management, computer technology, industry information, and marketing advice. It also offers Chinese medicine beauty services and e-commerce sales. Ma Kuang manages and operates numerous facilities, such as general clinics, community medical clinics, and traditional Chinese medicine clinics, alongside educational institutions. The company further diversifies its activities through the retail sale of dietary supplements, pharmaceuticals, and medical supplies in its stores, involvement in the restaurant industry, and offering leasing and other ancillary services.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$71.70+NT$0.20 (+0.28%)
Puriblood Medical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 23.48% below the high.
NT$30.15NT$0.00 (0.0%)
Concord Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.75% below the high.
NT$30.60-NT$0.05 (-0.16%)
Level Biotechnology Inc.’s quoted price sits in the lower half of its reported 52-week range, 11.82% below the high.
NT$15.40-NT$0.65 (-4.05%)
AmCad BioMed Corporation’s quoted price sits in the upper half of its reported 52-week range, 18.3% below the high.
NT$13.95-NT$0.05 (-0.36%)
LAUNXP Biomedical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
NT$36.00NT$0.00 (0.0%)
TCI GENE Inc.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$24.00NT$0.00 (0.0%)
Wiltrom Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 20.66% below the high.
NT$36.20-NT$0.20 (-0.55%)
DV Biomed Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.46% below the high.
